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Abstract
Background: Neuroinflammation following traumatic brain injury (TBI) has been shown to be associated with
secondary injury development; however, how systemic inflammatory mediators affect this is not fully understood.
The aim of this study was to see how systemic inflammation affects markers of neuroinflammation, if this
inflammatory response had a temporal correlation between compartments and how different compartments differ
in cytokine composition.
Methods: TBI patients recruited to a previous randomised controlled trial studying the effects of the drug anakinra
(Kineret®), a human recombinant interleukin-1 receptor antagonist (rhIL1ra), were used (n = 10 treatment arm, n =
10 control arm). Cytokine concentrations were measured in arterial and jugular venous samples twice a day, as well
as in microdialysis-extracted brain extracellular fluid (ECF) following pooling every 6 h. C-reactive protein level (CRP),
white blood cell count (WBC), temperature and confirmed systemic clinical infection were used as systemic markers
of inflammation. Principal component analyses, linear mixed-effect models, cross-correlations and multiple factor
analyses were used.
Results: Jugular and arterial blood held similar cytokine information content, but brain-ECF was markedly different.
No clear arterial to jugular gradient could be seen. No substantial delayed temporal associations between blood
and brain compartments were detected. The development of a systemic clinical infection resulted in a significant
decrease of IL1-ra, G-CSF, PDGF-ABBB, MIP-1b and RANTES (p < 0.05, respectively) in brain-ECF, even if adjusting for
injury severity and demographic factors, while an increase in several cytokines could be seen in arterial blood.
Conclusions: Systemic inflammation, and infection in particular, alters cytokine levels with different patterns seen in
brain and in blood. Cerebral inflammatory monitoring provides independent information from arterial and jugular
samples, which both demonstrate similar information content. These findings could present potential new
treatment options in severe TBI patients, but novel prospective trials are warranted to confirm these associations.
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Traumatic brain injury (TBI) is a devastating condition,
with an increasing morbidity and mortality [1, 2]. Fol-
lowing the primary impact, secondary injury mecha-
nisms play a major role in patient deterioration [3], and
of these pathologies neuroinflammation is acknowledged
as being one of the main drivers [4].
Patients with TBI have shown to present a peripheral
shift in their immune capacity, sometimes referred to as
a ‘TBI-induced peripheral immune suppression’, which
is also supported by TBI animal models [5–8]. Up to
50% of severe TBI patients have been suggested to suffer
from infections during their hospital stay [9]. A recent
study in mice exposed to Streptococcus pneumoniae and
to either TBI or sham surgery showed that brain-injured
mice were unable to demonstrate an appropriate im-
mune response due to impaired monocytic function in
both acute and chronic stages of TBI which resulted in
greater pulmonary bacterial loads [10]. In humans,
ventilator-associated pneumonia (VAP) is present in up
to 36% of TBI cases and is associated with a longer hos-
pital stay and increased morbidity [11].
Conversely, a systemic-to-brain inflammatory inter-
action has also been observed. Mice systemically injected
with endotoxin lipopolysaccharide (LPS) respond with
subsequent neuroinflammation, primarily via an acti-
vated potent microglial response and increased concen-
trations of pro-inflammatory cytokines, specifically
interleukin (IL)-1b, IL-6 and tumour necrosis factor
alpha (TNFa) [12–16]. An increased glial activation has
similarly been observed on positron emission tomog-
raphy (PET) scans of LPS-injected non-human primates
[17]. These systemic inflammatory stimuli have been
shown to impair cognitive functions and behavioural
changes [15], and are suggested to play an important
role in the development in conditions such as long-term
neuro-degeneration and psychiatric conditions following
inflammatory exposure [18].
In humans, there are several studies describing the
cytokine levels in central nervous system (CNS) infec-
tions, such as meningitis and encephalitis [19–21]. How-
ever, to the best of our knowledge, there are no studies
specifically analysing the neuroinflammatory response to
systemic inflammatory conditions, i.e. to infections ori-
ginating from outside the CNS, or to common systemic
inflammatory markers such as white blood cell count
(WCC), C-reactive protein (CRP) levels and high
temperature.
Due to the inaccessibility of the human CNS, there are
obvious logistical and ethical caveats concerning longitu-
dinal sampling and monitoring. Commonly, cerebro-
spinal fluid (CSF) cytokine levels are used as surrogates
for measuring cerebral inflammatory activity, including
in TBI [22, 23]. In addition, the jugular blood has been
suggested as a surrogate locale to measure neuroinflam-
mation due to its proximity to the brain, as compared to
arterial blood [24]. Another method for measuring brain
CNS cytokine levels is microdialysis (MD) [25], whereby
a catheter with a semi-permeable membrane is im-
planted in brain tissue following conditions such as se-
vere TBI where it enables monitoring of cerebral
metabolism, assisting in guiding therapy and interven-
tions [26].
Human recombinant IL-1 receptor antagonist
(rhIL1ra), a potent immunomodulatory drug currently
used for treating auto-immune conditions such as
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rheumatoid arthritis, has received a lot of interest in
treating CNS conditions [27]. Our group has undertaken
a phase II trial of rhIL1ra in TBI, where a panel of 42 cy-
tokines were measured in brain microdialysate for 5 days
following injury, noting that the subcutaneously admin-
istered drug reached the brain and shifted the cytokine
response in the brain extracellular fluid [28]. A similar
shift was also seen in the cytokine profile in arterial
serum [29], with the CNS cytokine profile shift being
time-dependent. Yet, it is still unknown to which extent
the inflammatory state of the brain is affected following
systemic inflammation by conditions such as severe in-
fections. If it were established that a systemic inflamma-
tory condition affected the brain, it could highlight a
potential treatment avenue for improved management of
acute CNS conditions, an area where there is a paucity
of pharmaceutical options.
We aimed to use safety-data collected in a previously
performed prospective trial of rhIL1ra in order to study
if systemic cytokine levels, as well as other markers of
inflammation and infection, are associated with cerebral
cytokine levels (from MD-retrieved extracellular fluid
(ECF)). As secondary aims, we wished to study the tem-
poral interaction to see if systemic inflammation pre-
cedes brain inflammation, or vice-versa. Additionally, we
studied the jugular cytokine levels to see how they com-
pare to arterial and cerebral levels.
Methods
Patient population and treatment
This patient population has been described in detail in
the previous studies [28, 29]. In short, n = 20 TBI pa-
tients (n = 10 drug, n = 10 no drug) with predominantly
diffuse injury were included in the randomised clinical
trial to study the efficacy of rhIL1ra on cytokine profiles
(REC# 06/Q0108/64). Ethical assent was collected from
next of kin. Patients randomised to the treatment arm
were administered 100 mg rhIL1ra (Anakinra, brand
name Kineret®, Sobi, Stockholm, Sweden) once daily
subcutaneously for 5 days. Apart from this, all patients
received standard neuro-critical care, as described [30],
for their TBI.
Microdialysis and blood sampling
A detailed description can be found in the original publi-
cation [28]. In short, brain ECF was acquired using a mi-
crodialysis catheter (CMA 71, 100 kDa molecular weight
cutoff) perfused with 3.5% (w/v) Human Albumin Solu-
tion (Pharmacy Manufacturing Unit, Ipswich Hospital
NHS Trust, Ipswich, UK) composed in central nervous
system perfusion fluid. Microdialysate collection vials
were changed hourly, and samples were pooled from a
6-h epoch to allow sufficient volume to assay.
Blood samples were taken concurrently into EDTA
tubes, from arterial and jugular venous catheters at 1 h
before and after rhIL1ra administration. The blood was
immediately centrifuged at 15 min at 4000×g. at 4 °C
and the supernatant extracted and stored in − 80 °C until
analysis. Plasma samples had sufficient volume for ana-
lysis without requiring dilution or pooling.
Clinical management and parameter definitions
C-reactive protein (CRP) and white blood cell count
(WCC) were analysed simultaneously one hour before
and one hour after the daily administration of anakinra
or no drug using conventional hospital laboratory equip-
ment at Addenbrooke’s Hospital, Cambridge, UK. Core
body temperature was measured at the same time using
a nasopharyngeal temperature probe. Confirmed clinical
infection was defined as an aggregate of clinical, labora-
tory parameters and cultures, and/or initiation of treat-
ment, and commenced when the condition was defined.
VAP was defined as per guidelines laid forth, at the time,
by the American Thoracic Society (ATS) and the Infec-
tious Diseases Society of America (IDSA) [31]. No pa-
tient suffered from a confirmed infection originating
from the CNS.
Acquired clinical and demographic data included age,
biological sex, motor score component of the Glasgow
Coma Scale (GCSm) [32] on admission, Injury Severity
Score (ISS) [33] and computerized tomography (CT) se-
verity scoring assessed as per the Stockholm CT-score
[34]. Deterioration on follow-up CT scan was noted.
Cytokine assay
Samples were analysed using the Milliplex Multi-Analyte
Profiling Human Cytokine/Chemokine 42 analyte pre-
mixed kit (Millipore, St Charles, MI, USA) using the
manufacturer’s instructions as described previously [28];
the 42 cytokines and chemokines assayed are detailed in
Additional file 1. All samples were assayed in duplicate
wells (25 μL per well) and the mean of the ensuing re-
sults was used. The plates were read using a Luminex
200 analyser (Luminex Corporation, Austin, TX, USA)
using the STarStation software (Applied Cytometry Sys-
tems, Sheffield, UK). Cytokine concentrations were cal-
culated by reference to an eight-point five-parameter
logistic standard curve for each cytokine.
Statistical analysis
Statistical analysis was performed using R, version 3.6.2
and RStudio, version 1.3.1073 for Macintosh. The
methods included principal component analysis and
multiple factor analysis, performed using the package
‘FactoMineR’ [35]; cross-correlation analysis, performed
using ‘ccf’ from base R; and linear mixed-effects model-
ling, performed using the package ‘nlme’ [36]. Other
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packages used include ‘messageR’ [37], ‘ggplot2’ [38] and
‘gplots’ [39]. The full reproducible code is available in
Additional file 2.
Principal component analyses and multiple factor analysis
of cytokine compartments
In order to investigate whether the cytokines recovered
from brain-ECF, and arterial and jugular venous plasma
demonstrate different information, we conducted princi-
pal component analysis (PCA) and multiple factor ana-
lysis (MFA). The analysis was performed using the
FactoMineR package in R, applying default configura-
tions of the PCA function, such as scaling the data to
unit variance. Any timepoints with incomplete data, i.e.
zero values, were omitted. Furthermore, potential cyto-
kine gradients between jugular and arterial cytokines
were studied, using the cytokine levels, grouped by pa-
tient. MFA is an extension to PCA, by which it is pos-
sible to analyse groups of variables [40]. In this case, an
MFA was deployed on the three fluid compartments as
groups.
Cross-correlations of inter-compartmental dynamics of
cytokines
In order to investigate the direction of cytokine level
changes between the different compartments, we per-
formed cross-correlation analyses on all cytokines be-
tween brain-ECF and arterial blood. Each time lag was
approximately 6 h; the timings of the blood samples
were matched to the appropriate time interval during
which the brain-ECF samples were drawn. We used the
‘ccf’ function in R to find the cross-correlations and cal-
culated the signed absolute maximum value for each
cytokine and patient time series (plotted using the
‘ggplot2’ package). An exclusion algorithm was
employed in order to select robust cross-correlation
series (Additional file 3).
Linear mixed-effect models
In order to investigate whether systemic inflammation
was associated with cerebral inflammation (i.e. brain-
ECF cytokine levels), we used linear mixed-effect
models. As fixed effects, we entered the cytokine level in
arterial blood, CRP, WCC, temperature, confirmed clin-
ical infection, rhIL1ra treatment and time from TBI
(without any interaction terms). For each model, p
values were extracted; no correction for multiple testing
was used as we had an unbiased approach and our scope
was not to identify a particular cytokine of importance.
Finally, the coefficients of the models were normalized,
and visualized as heatmaps, using the ‘massageR’ and
‘gplots’ packages. A similar analysis was performed pre-
dicting arterial cytokine levels, but here replacing the
parameter ‘arterial cytokine’ with the brain-ECF
counterpart.
Blood and brain-ECF samples were not acquired sim-
ultaneously (Additional file 4). Since the time variable
primarily serves as a predictor of the brain-ECF cyto-
kines and as a parameter in the correlation structure of
the linear mixed-effect model, we used the correct
brain-ECF sampling times and subsequently matched
the blood sampling times with these. As random effects,
we had intercepts for patients, as well as by-patient ran-
dom slope for the effect of time. Similar models were
then used to predict brain-ECF and arterial cytokine
levels, with clinical and admission parameters (age, sex,
GCSm, ISS and Stockholm CT score) as independent
variables. The strongest signals, based on the number of
significant cytokines in the linear models of both com-
partments, were then combined with inflammatory
markers into a final analysis.
Further details can be found in the supplementary
statistical text (Additional file 3).
Results
Patient demographics and missing analytes
The patients included in this study have been previously
described in detail [28]. In summary, the twenty recruited
patients (10 females, 10 males) had predominantly diffuse
injury, all with a post-resuscitation GCS of less than 8
(traditionally considered a ‘severe’ TBI). A relatively large
variation can be observed between patients in trends of
WCC, CRP and temperature during the first 5 days fol-
lowing the TBI (Additional file 1). Apart from a more sub-
stantial decrease in CRP in the intervention group
compared to the control group, there were no significant
differences between the groups in terms of inflammatory
markers. Both treatment groups experienced four infec-
tions each requiring treatment, a majority of these were
VAPs. Five of these were reported as SAEs as per the pre-
specified definitions [28]. Median levels of CRP, WCC,
temperature as well as admission CT scores and injury
characteristics can be seen in Table 1.
On average, cytokines measured in arterial and venous
jugular plasma, and brain-ECF compartments, had miss-
ing rates of 18.5%, 30.9% and 26.3%, respectively (Add-
itional file 1). There were no apparent differences in
distribution of missing data between the two treatment
groups, compartments or patients, but there was a dif-
ference in missing rate (frequency of absence) between
different cytokines. This indicates that missingness
might not be random, but presumably related to the
Luminex assay’s capabilities to measure specific cyto-
kines (such as IL-4, which is known from previous stud-
ies [42]). The missingness of IL-4 in microdialysates is
unlikely to be due to poor relative recovery, as previous
studies in vitro have shown IL-4 to be well-recovered
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(57%) using the same type of 100 kDa microdialysis
catheter used in the present study [25]. Patient C04 had
no cytokine measured in jugular blood due to clotting of
the catheter.
Arterial and jugular compartments provide similar
information
For each cytokine, a variables factor map was plotted
(Additional file 2: Figure 3A code) and visually analysed.
Most cytokines exhibit a similar pattern: the axes corre-
sponding to arterial and venous cytokine concentrations
are adjacent to each other and near the first principal
component axis, while the brain-ECF axis is approxi-
mately orthogonal to these and near the second princi-
pal component axis. Consequently, variations seen in
arterial blood are generally corresponding to variations
found in jugular venous blood, indicating that the two
samples carry similar information and that this is differ-
ent from the information carried by brain-ECF
concentrations.
Figure 1 shows the groups’ representation of the
MFA (Fig. 1A), where the dichotomy between the
brain-ECF and the blood plasma samples is evident,
as well as the similarity of information in arterial and
venous blood samples. This includes the arterial-
venous gradient which was localized differently from
the blood compartments, but more similar to them as
compared to the cerebral compartment (Fig. 1A). As
shown by linear correlations, the blood and brain
compartments did not correlate (Fig. 1B), while there
was a strong correlation between the arterial and
jugular compartments for all cytokines with signifi-
cant data (Fig. 1C). Due to these similarities, only ar-
terial blood was used in future analyses due to lower
levels of missingness.
The median arterial-jugular (AJ) gradient for each
cytokine is shown in Table 2 (and in Additional file 2:
Table 2 code). As can be seen, 28 cytokines had a posi-
tive AJ gradient, having higher concentrations in arterial
blood than in jugular venous blood. Accordingly, 14 cy-
tokines had higher concentrations in the venous com-
partment. Hence, these results oppose the idea that
there is a one-way flow of cytokines from the injured
brain to the blood, and that in general, the level of















C01 12.4 (8.7–15.3) 94 (63–114) 37.07 (36.82–37.5) – – 1.5 45
C02 1.5 (0.6–3.4) 172 (37–250) 37.3 (35.83–37.88) – Yes 0.5 38
C03 14.85 (13.5–20.2) 147 (52–250) 36.92 (35.65–37.93) VAP – 1 45
C04 10.4 (8.4–15.7) 182 (103–250) 36.17 (33.07–37.75) VAP Yes 3 33
C05 21.5 (16.5–26) 216 (26–250) 36.47 (35.45–38.1) VAP – 2.5 38
C06 8.1 (5.7–16.7) 136.5 (45–143) 36.03 (34.72–37.15) – – 1.9* 38
C07 9.1 (6.8–18.3) 187 (5–250) 35.42 (35.02–37.72) – – 2 29
C08 7.1 (6.4–10.4) 131.5 (107–250) 37.19 (36.63–37.4) – – 3 36
C09 9.55 (8.2–10.7) 136.5 (47–194) 36.36 (34.48–37.72) – – 0.5 38
C10 4.7 (0.9–13.5) 250 (92–250) 33.21 (32.92–35.42) IAS Yes 4 30
I01 7.8 (7.8–9.8) 104.5 (48–186) 36.1 (35.88–36.65) – – 3 27
I02 12.35 (7.8–22.1) 74 (18–250) 36.92 (36.32–38.3) CI Yes 3 43
I03 5.6 (4.4–8.1) 181 (152–211) 35.37 (34.3–35.67) – – 2.4* 50
I04 10.4 (7.2–16.1) 230 (162–250) 38.13 (37.17–39.68) – Yes 3 50
I05 14.3 (4.9–23.4) 238 (128–250) 35.48 (34.95–37.97) VAP Yes 1.5* 30
I06 11.45 (7.3–12.7) 102 (26–201) 37.28 (36.83–37.72) VAP Yes 3.8 27
I07 7.7 (5.8–14.2) 64 (38–150) 34.55 (33.12–37.02) – – 2* 45
I08 6.15 (4–8.3) 96.5 (31–204) 36.92 (36.57–37.17) – – 2 66
I09 11 (7–15.3) 113 (2–239) 37.47 (36.87–37.62) VAP – 1.5* 43
I10 7.15 (4.7–13.4) 76 (17–158) 36.58 (36.08–37.45) – – 3 27
The first ten patients are control (C) patients and the other ten patients are intervention (I) patients receiving rhIL1ra treatment. White cell count, C-reactive
protein (CRP) and temperature are displayed as median values, with maximum and minimum values in parentheses; their respective units are number of 109 cells
per liter, μg/ml and °C. Infection types are ventilator-associated pneumonia (VAP), intraabdominal sepsis (IAS) and chest infection (CI). Stockholm CT score and
injury severity score (ISS) are defined as in [34, 41], respectively. CT scores with an asterisk indicate a deterioration on subsequent scan
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cytokines are in fact higher in arterial blood in NCCU
treated TBI patients.
No temporal trends between compartments could be
visualized
In order to investigate the direction of cytokine level
changes between the different compartments, we per-
formed cross-correlation analyses on all cytokines be-
tween their levels in brain-ECF and in arterial blood.
Figure 2 depicts a fairly even distribution of cytokines in
the four quadrants of the signed absolute maximum
mean cross-correlation plot. The points are distributed
such that there is a global symmetry around lag zero for
both positively and negatively cross-correlated cytokine
and patient series. This indicates that there is no ob-
served global trend in neither directionality in move-
ment between the blood and brain-ECF compartments
nor in relative concentration changes between the two
compartments.
Although there might not be an average global
trend for all 42 cytokines in the 20 patients included
in this study, individual cytokines or patients could
have distinct patterns. In an attempt to address this
hypothesis, we visually examined plots for every cyto-
kine, as well as plots for every patient, annotated with
the same parameters. Generally, we find a similar pic-
ture when visualizing individual cytokines as seen in
Fig. 2 when all cytokines were combined (Additional
file 2: Figure 2 code). While no individual cytokine
showed any significant delayed temporal association,
notable cytokines include eotaxin, IFN-γ, and MIP-1a
which trended from brain to blood, while others
showed a predominant delayed temporal association
from blood to brain, such as IL-1α and IL-6 and the
anticipated IL1ra which was given systemically (Add-
itional file 2: Figure 2 code).
Markers of systemic inflammation affect brain cytokine
levels
Among the systemic inflammatory markers, confirmed
systemic clinical infections resulted in the largest relative
effects on brain-ECF levels. Infections increased brain-
ECF levels of, e.g. IL-1b and decreased levels of, e.g. IL-
1ra (Fig. 3A and Additional file 5). rhIL1ra treatment re-
sulted in significant alterations of both the systemic and
neuroinflammatory responses (Fig. 3A). In brain-ECF,
Fig. 1 Relationship between brain extracellular fluid (ECF) and blood compartments. A Multiple factor analysis of compartments as groups. The
arterio-jugular venous (A-V) gradient is plotted as a supplementary variable, while the other variables are active. Displayed on the right, there is
an example of the log-log plot of B brain ECF vs arterial blood and of C jugular venous vs arterial blood concentration of IL-6—the cytokine with
least missing data
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Table 2 Median difference between arterial (A) and jugular (J) venous cytokine concentrations
Cytokine Abbreviation A–J [pg/mL]
Epidermal growth factor EGF 1.19
Eotaxin Eotaxin − 0.207
Basic fibroblast growth factor FGF.2 0.641
Fms-related tyrosine kinase 3 ligand FLT.3.ligand − 2.053
Fractalkine/CX3CL Fractalkine − 0.662
Granulocyte colony-stimulating factor G.CSF − 3.413
Granulocyte-monocyte colony stimulating factor GM.CSF − 0.388
GRO/CXCL3 GRO 20.593
Interferon alpha-2 IFNa2 0.476
Interferon gamma IFNg − 0.172
Interleukin-1 alpha IL.1a 1.654
Interleukin-1 beta IL.1b − 0.055
Interleukin-1 receptor antagonist IL.1ra 2.157
Interleukin-2 IL.2 0.313






Interleukin-9 IL.9 − 1.634
Interleukin-10 IL.10 0.894





Chemokine (C-X-C motif) ligand 10 IP.10 − 1.628
Monocyte chemotactic protein 1 MCP.1 − 0.658
Monocyte chemotactic protein 3 MCP.3 0
Macrophage-derived chemoattractant MDC 19.1
Macrophage inflammatory protein-1 alpha MIP.1a 1.333
Macrophage inflammatory protein-1 beta MIP.1b 2.014
Platelet-derived growth factor AA PDGF.AA 19.988
Platelet-derived growth factor AB/BB PDGF.ABBB 201.807
RANTES RANTES 88.263
Soluble CD40 Ligand sCD40L 16.129
Soluble interleuking-2 receptor sIL.2Ra 7.785
Transforming growth factor alpha TGFa 0.47
Tumour necrosis factor alpha TNFa 0.7
Tumour necrosis factor beta TNFb 0.741
Vascular endothelial growth factor VEGF 2.574
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EGF, IFN-γ, IL-9 and MDC were statistically significant,
all of which were associated with lower cerebral cytokine
levels for the treatment group. High WCC and
temperature generally showed associations to increased
cerebral levels of cytokines, with stronger associations
for WCC (Fig. 3A). Levels of CRP generally showed
weaker normalized coefficients, and the clustering was
most associated with arterial cytokine levels. Notably, in-
creases in arterial cytokines were not necessarily associ-
ated with brain-ECF cytokine levels highlighting the
difference between the two compartments.
Using a similar approach to see which parameters
affect blood cytokine levels, confirmed systemic infec-
tions seemed to have the strongest positive association
with several cytokines in blood, notably IL-6, IL-8 and
IL-10 (Fig. 3B and Additional file 5). On a group level,
CRP was more associated with increased blood cytokine
levels than brain cytokine levels. Time from study inclu-
sion also seemed to affect blood cytokine levels, but not
as much as brain-ECF levels, and not as many cytokines
decreased in blood over time as in the brain (Fig. 3B).
Similar to the brain-ECF levels, rhIL1ra treatment re-
sulted in a distinct separation between cytokines that
were altered in blood, though these were not the same
as those affected in the cerebral compartment.
Altogether, these results highlight marked differences in
the down-stream cytokine response to inflammatory
stimuli in brain compared to its systemic counterparts.
The systemic effect on brain-ECF levels remain following
adjustment of baseline and injury severity parameters
Similar mixed-models were used to illustrate cytokine
patterns using demographic and injury severity parame-
ters. Interestingly, these quite strongly affected both
brain-ECF and blood cytokine levels (Additional files 5-
6). An increasing age was associated with increasing
cytokine levels in brain-ECF, while lower levels in blood
(Additional file 5). Similarly, female sex was associated
with higher levels of cytokines in brain-ECF while the
inverse was shown for blood cytokine levels where fe-
male sex was associated with a decrease for a majority of
cytokines (Additional file 5). Stockholm CT score, ISS
and GCSm showed relatively similar cytokine trends,
clustering in proximity (Additional file 5).
When combining demographic- and injury severity pa-
rameters with ‘clinical infection’ as our choice of infec-
tion marker, there were still brain-ECF cytokine levels
independently associated with the development of a sys-
temic infection (IL1-ra, G-CSF, PDGF-ABBB, MIP-1b
and RANTES, p < 0.05 respectively) (Fig. 4A, B and
Additional file 6). Interestingly, all these cytokines sig-
nificantly decreased in brain-ECF following during. Since
most patients with infection were female (7/8), an inter-
action term between sex and infection was added to this
model. Interactions were not significant in any of the cy-
tokines with significant coefficients for the impact of in-
fection, and were significant only in three cytokines with
Fig. 2 Signed absolute maximum cross-correlations of brain and blood cytokine time series. For every cytokine and patient, the signed absolute
maximum of the cross-correlation series of cytokines in extracellular brain fluid and arterial blood was recorded as the y-value, and the lag at
which this occurred was recorded as the x-value. Each lag represents 6 h
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significant coefficients for the impact of sex (Fig. 4A). In
blood, clinical infections now showed a significant in-
crease in fourteen cytokines (Fig. 4B), more than any
other variable. rhIL1ra treatment showed similar trends
following these types of adjustment for both brain and
blood cytokines (Fig. 4A, B).
The different cytokine trends before and after the de-
velopment of a clinical infection for brain-ECF and
blood (of cytokines significant in Fig. 3A) are also visual-
ized in Fig. 5. Here, it can be seen that arterial levels of
cytokines are generally higher, and have an upwards
trend while the opposite is shown for a majority of the
brain-ECF cytokines.
Discussion
We have demonstrated that following human TBI, there
are distinct cytokine profiles that differ between blood
and brain in response to systemic markers of inflamma-
tion, specifically infections, as well as an effect of anti-
inflammatory treatment. To the best of our knowledge,
this is the first study to study the interplay between per-
ipheral/systemic markers of inflammation and cerebral
cytokine levels in acute CNS conditions in humans.
Peripheral inflammation modulates cerebral inflammation
The cytokine profile in brain-ECF was altered following
the development of a systemic infection with a signifi-
cant decrease seen in five cytokine concentrations (IL1-
ra, G-CSF, PDGF-ABBB, MIP-1b and RANTES), while
an increase in several cytokines were simultaneously
seen in blood. Due to the inaccessibility of the human
CNS, studies looking at simultaneous cerebral and sys-
temic inflammation in living humans are scarce. In an
autopsy study from n = 21 TBI patients, they noted an
increase of IL-6, IL-8, TNFa and IL-1b mRNA levels
which are significantly increased in tissue following in-
jury [43]. They concluded that pro-inflammatory cyto-
kines play a key role in the cerebral inflammatory
response following TBI, but did not adjust for the influ-
ence of systemic infections/inflammation. Autopsy
Fig. 3 Coefficients of linear mixed effect models, displayed as heatmaps. The colours of the heatmaps are graded such that red represents
positive coefficients and blue represents negative coefficients. All coefficients are normalized using the quotient of their standard deviation and
that of the dependent variable. Significant coefficients are highlighted with an asterisk. Independent variables are along the y-axis and the
dependent variable for each model is the cytokine of the respective row on the x-axis in either A the brain extracellular fluid or B arterial blood.
Differences in cytokines displayed between the two subfigures are due to insufficient data to generate all coefficients from the model. EGF
epidermal growth factor, FGF.2 basic fibroblast growth factor, FLT.3.ligand Fms-related tyrosine kinase 3 ligand, G.CSF granulocyte colony
stimulating factor, GM.CSF granulocyte-monocyte colony stimulating factor, IFNa2 interferon alpha-2, IFNg interferon gamma, IL interleukin, IL-1R
interleukin 1 receptor, IL1ra interleukin-1 receptor antagonist, IL12p40 interleukin 12 subunit beta, IL12p70 interleukin-12, IP10 chemokine (C-X-C
motif) ligand 10, MCP monocyte chemotactic protein, MDC macrophage-derived chemoattractant, MIP1a macrophage inflammatory protein-
1alpha, MIP1b macrophage inflammatory protein-1beta, PDGF platelet-derived growth factor, RANTES chemokine (C-C motif) ligand 5, sCD40L
soluble CD40 ligand, sIL.2R soluble interleuking-2 receptor, TGFa transforming growth factor alpha, TNFa tumour necrosis factor alpha, TNFb
tumour necrosis factor beta, VEGF vascular endothelial growth factor
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studies from patients that have died with sepsis reveal a
distinct increase of microglia activation and astrocytosis
as compared to non-sepsis controls [44, 45]. In an aut-
opsy study by Warford et al, they noticed an increase of
predominantly chemokines in sepsis patients, while
TNFa was increased in all patients, IL-1b expression was
upregulated in 2 out of 3 patients [45]. Unfortunately,
neither the TBI or sepsis autopsy studies analysed the
cytokines significantly decreasing in brain-ECF following
systemic infections in our study. Patients with TBI and
subarachnoid haemorrhages (SAH) that develop sepsis
have been shown to exhibit higher levels of IL-6 in blood
during the first week following ictus [46, 47], but not in
CSF [48], showing similar differences between the blood
and brain compartments seen in our study, and potential
differences between studies analysing fluid vs tissue
cytokine levels.
rhIL1ra treatment resulted in a strong alteration of
brain and blood cytokine levels. Treatment with rhIL1ra
in trials of human SAH have resulted in lower levels of
IL-6 in both serum and CSF [49, 50], thus there is evi-
dence that the drug will alter cytokine levels in several
compartments following brain injury. Unfortunately, to
our knowledge, there are no studies multiplexing cyto-
kines following rhIL1ra treatment, making it difficult to
compare our findings, though our new mixed-model in
part validates the previous results found with different
statistical approaches in the same material [28, 29].
While WCC, temperature and CRP levels were shown to
be associated with cytokines, we believe clinical infection
represent the best aggregate of inflammatory markers
and a judgement call of the treating physician, why we
used it throughout the manuscript to define systemic in-
flammation. Interestingly, WCC, temperature and CRP,
Fig. 4 Coefficients of linear mixed effect models, displayed as heatmaps. The colours of the heatmaps are graded such that red represents
positive coefficients and blue represents negative coefficients. All coefficients are normalized using the quotient of their standard deviation and
that of the dependent variable. Significant coefficients are highlighted with an asterisk. An interaction term between female sex and infection.
Independent variables are along the y-axis and the dependent variable for each model is the cytokine of the respective row on the x-axis in
either A the brain extracellular fluid or B arterial blood. Differences in cytokines displayed between the two subfigures are due to insufficient data
to generate all coefficients from the model
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commonly aggregated when defining infections, as well
as almost all the cytokines, exhibit different information
content (Additional file 7). Additional file 7 also demon-
strates that, due to collinearity, the variable ‘clinical in-
fection’ largely captures all these other inflammatory
markers making it a suitable marker for systemic inflam-
mation. While we specifically adjusted for time when
analysing cytokine levels, we only implicitly used the
timing of an infection by coding the infection parameter
as 0 outside the time of infection and as 1 during an in-
fection. Therefore, we did not draw any conclusions of
differences between patients with early or late infections,
respectively. However, this approach could at least to
some extent account for timing of infection in the
model.
Patient demographics affect cytokine levels
The demographic and injury severity markers all showed
some significant associations with alterations on cyto-
kine levels in both brain-ECF and blood. Female sex was
associated with higher cytokine levels in brain-ECF and
lower levels in blood, as compared to males, after
Fig. 5 Cytokine levels before and after infection for patients with infection. Cytokines significant for infection in the heatmaps are shown as
logarithms. The gap between data before infection and after infection is the time of uncertainty from last known non-infection to first known
infection. The standard error of the mean was used to compute 95% confidence intervals
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adjusting for interaction with infection, in which female
patients were overrepresented. Sex differences concern-
ing cytokine responses in humans have previously been
shown [51, 52]. Mellergård and colleagues demonstrated
in a cohort of SAH and TBI patients that IL-1b and IL-
6, extracted from brain-ECF using MD, were higher and
increased for a longer period in females compared to
males [53]. Similarly, these cytokines were higher in fe-
males in our study as well, though several other cyto-
kines exhibited even higher concentrations. In another
study by Majetschak and co-workers, they could not see
a sex difference in post-traumatic cytokine release in
blood in a trauma cohort of n = 89 patients [54]. Older
age was shown to increase levels of cytokine in brain-
ECF, but decrease cytokine levels in blood. In the pre-
clinical literature, TBI in the aged brain is often consid-
ered more detrimental due to a maladaptive neuroin-
flammatory response [55, 56], which could explain the
increased cytokine response seen in brain-ECF in our
study. In mild TBI, patients > 55 years old (compared to
21–54 years) levels of, e.g. IL-6, TNF and fractalkine
were elevated in blood up to 6 months following injury
[57]. TBI and polytrauma patients exhibit clinically rele-
vant cytokine patterns in blood [58–60], CSF and brain-
ECF [22], which was similar to what we noticed in our
cohort, and demonstrates cytokine release from brain
and other injured tissues.
No clear delayed temporal association was seen between
brain and blood cytokines
In general, we could not see any clear trends for cyto-
kines moving from brain to blood, or vice versa. This
could indicate that the movement between compart-
ments occurs in a time frame much shorter than the
sampling interval, and half-lives in vivo have been sug-
gested to be short and thus cytokine concentrations very
dynamic and could be difficult to assess [61]. However,
the levels of some selected cytokines, like IL-6, IL-8 and
TNFa, have been shown to be relatively stable for days
following TBI in both serum and CSF, with selected
cytokine concentrations higher in CSF than in serum
[62, 63]. There are several studies that have serially sam-
pled cytokines following human TBI in both serum and
brain [42, 62, 64], but to the best of our knowledge we
are the first to attempt a temporal cross correlation be-
tween brain-blood compartments. As is seen in these
TBI studies, it is entirely possible that the gradient be-
tween compartments is such that the cytokine move-
ment could follow a cerebral to systemic direction, as
well as a systemic to brain as suggested by the preclinical
studies using systemic LPS stimulation [13]. Further, a
possible explanation for not being able to see any over-
arching temporal associations could be that the 6h
pooled epochs of brain microdialysates are too long to
detect rapid cytokine fluxes. Moreover, our results could
also reflect any inherent differences and circumstances
concerning cytokine generation/degradation or con-
sumption in brain-ECF and blood, respectively. This is
supported by the cytokine concentration similarities
found in both arterial and jugular blood vs brain-ECF.
Some cytokines showed a predominant delayed temporal
association from brain to blood and vice-versa, but
altogether, while we cannot rule out that temporal corre-
lations and fluxes are absent due to intrinsic compart-
mental differences, future techniques might make more
frequent sampling possible.
Both arterial and jugular compartments hold similar
information content
There was no difference in cytokine levels between jugu-
lar- and arterial blood, as compared to the distinctly dif-
ferent brain-ECF compartment. A jugular-arterial
gradient has been suggested with higher levels of cyto-
kines and brain protein biomarkers in blood, indicative
of a cerebral source of these markers [24, 65]. In fact, we
noticed that more cytokines were higher in arterial blood
as compared to jugular blood, which could indicate that
a systemic inflammation masked any increase of cyto-
kines in the jugular compartment. Jugular samples had a
higher degree of missingness, but it is uncertain how this
would affect the analyses. McKeating and colleagues
looked at the jugular-arterial gradient in a mixed cohort
of TBI and SAH patients, and noted a trans-cranial gra-
dient of IL-6 with higher levels in jugular as compared
to arterial blood the first 48 h after injury [24] (this
could not be seen in our material (data not shown)).
They could not see any difference for IL-1b, TNFa or
IL-8, which could be due to a significant amount of
missing data in their study (86%, 88% and 52%, respect-
ively) [24]. Possibly, the effective half-life of any brain-
released cytokines is longer than the time it takes to
reach the arterial compartment. Additionally, any
marker that can only be accessed in a jugular compart-
ment is in all likelihood too erratic to act as a good
marker of neuro-inflammation clinically.
Clinical implications
It is currently unclear how a systemic inflammation im-
pairs cerebral functions and causes an inflammatory re-
sponse, though it has been shown that concomitant
infections in TBI increase the risk of an unfavourable
outcome [9]. Several theories suggest that cytokines in
blood targets different cerebral receptors, resulting in,
for example, drowsiness, effects on the circulation and
respiration, hyperthermia and cognitive implications [66,
67]. However, we can demonstrate that systemic infec-
tions not only result in extensive increase of cytokines in
blood, but also alter the cytokine levels in brain-ECF.
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This suggests that infections in TBI patients could bene-
fit from more aggressive treatment, as their brain is pre-
sumably more susceptible to this potentially detrimental
neuroinflammatory response [9] with potential impacts
on both the immunological response to infection and a
detrimental inflammatory response with respect to the
TBI. However, due to the low sample size, we could not
associate these cytokine dynamics with brain pathology
or outcome, limiting the results to an exploratory and
preliminary nature, and further research in larger co-
horts is necessary. Interestingly, levels of IL-6 and IL-8
seen in patients suffering from Covid-19 have been
shown to be similar to those of trauma patients [68]. As
the notorious ‘cytokine-storm’ in this disease, as well as
many other septicaemias, have been attributed to an un-
favourable outcome, we believe that cytokine monitoring
of both brain and blood compartments are crucial in
order to better understand the pathophysiology and to
device new anti-inflammatory treatment strategies for
brain injured patients.
Limitations
Due to ethical restraints, there is a lack of proper con-
trols without a concomitant brain injury. We are limited
to TBI patients where microdialysis catheters are
inserted as part of clinical management (while usually
harmless, insertion of these catheters may result in hae-
morrhages and infections [69]). Thus, it becomes diffi-
cult to assess exactly what cytokine signal that comes
from the injured brain and what may be the result of a
peripheral infection. However, we did attempt to adjust
for both ISS as a marker of extracranial injury severity
and Stockholm CT-score as a marker of intracranial in-
jury severity (as well as other demographic factors) in
order to filter out the exact contribution of the systemic
inflammation. Furthermore, we tried to address these
questions in relatively small sample size of only 20 pa-
tients, where we parametrized the inter-patient variabil-
ity (Additional file 3). However, for each block seen in
the heatmaps (Figs. 3 and 4), a total of 382 data points
were used in generating the results. In short, our
methods allow us to include all the acquired brain-ECF
samples, adjusted for individual patients over time, in
order to conduct our analyses. That being said, the low
sample size in this study renders the results exploratory
and requires validation in larger prospective trials.
As has been highlighted in previous microdialysis
studies, the relative recovery (levels of cytokines ex-
tracted through the pores in the microdialysis catheter/
actual level of cytokines in a fluid) will strongly influence
the levels measured in brain-ECF [25, 70]. As can be
seen in Additional file 1, there are a few cytokines with a
lot of missing data from the brain-ECF compartment
(e.g. IL-4), highlighting the limitations of the current
method for these selected cytokines. However, there are
no other methods available to access the brain-ECF
in vivo than microdialysis, and the Luminex technology
is still amongst the more sensitive methods for multi-
plexing small volumes while also retaining a standard
curve for absolute concentrations. The technique to
measure cytokines in brain-ECF is also largely unavail-
able outside of the research setting, and is currently as-
sociated with substantial costs, obstructing translation
into main-stream clinical use.
Previous studies studying cytokines in TBI often select
one or a few, and assign them attributes being ‘pro-’ or
‘anti-inflammatory’ [22]. The inflammatory pathways are
often more complex than this, so we believe that this
simplification could potentially skew our understanding
by attributing biological function to cytokines that are
easy to measure using a particular technique. By multi-
plexing > 40 cytokines from several compartments, we
instead chose to focus on them all in a more unbiased
fashion. Out of the seven SAEs reported in the study,
five were infections. The other two were neutropenia of
unknown etiology (in the control group), and right
upper lobe lung collapse after bronchoscopy to remove
traumatic clots (in the treatment group). While we be-
lieve that infections are the most likely cause of alter-
ations in brain and blood cytokine levels, it is possible
that these other two (non-infection) events resulted in
cytokine changes as well.
Conclusions
Systemic inflammation alters the cerebral inflammatory
response with lower levels seen in brain-ECF, while
higher levels were seen in blood, which remains after
adjusting for relevant demographic and injury severity
markers. rhIL1ra treatment affected systemic and cere-
bral cytokine levels, demonstrating the effect of anti-
inflammatory treatment following TBI. Venous jugular
and arterial compartments contain similar cytokine in-
formation following TBI, while the cerebral compart-
ment has a unique profile. While these results should be
considered exploratory due to the small sample size, im-
proved monitoring of the neuroinflammatory response
and better management of systemic infections could po-
tentially improve outcome in acute brain injuries, al-
though larger trials are needed to confirm these
assumptions.
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Additional file 1. Title of data: Baseline data. Description of data:
Columns for the first eight rows are for each patient (C, control; I,
intervention); moreover, the first four rows have time along the
horizontal axis. Columns for the final row are for each cytokine. Rows 1-3
display changes over time of white cell count (WCC), C-reactive protein
(CRP) and temperature, with corresponding lines of best fit. Row 4 dis-
plays infection status of patients over time. Row 5 shows infection (VAP,
ventilator-associated pneumonia; IAS intra-abdominal sepsis; CI, chest in-
fection), severe adverse events (SAE), sex (M, male; F, female) and years of
age for each patient. Row 6 shows Stockholm computed tomography
(CT) score for each patient, coloured after whether a deterioration was
observed during hospital stay. Row 7 shows injury severity score (ISS) for
each patient. Row 8 shows fraction of missingness in each compartment
and for each patient. Row 9 shows fraction of missing cytokines in each
compartment. The chest infection was a result of mucous plugging
resulting in a right lower lobe collapse, hence not fulfilling VAP criteria.
Additional file 2. Title of data: Code. Description of data: Code for
generating all figures and tables provided. Order of appearance: Figures
1-5, Tables 1-2, Additional file 6-7. Additional file 5 is generated by code
for Figures 3-4.
Additional file 3. Title of data: Mixed models details. Description of
data: Statistical details.
Additional file 4. Title of data: Timing of blood samples and cytokine
pooling. Description of data: Illustrating the timing between microdialysis
samples, blood compartment samples and recombinant human
Interleukin 1 receptor antagonist (rhIL1ra) treatment. Microdialysis
sampling (green) were pooled during 6 h epochs throughout the study.
The rhIL1ra treatment was administered once daily to patients in the
treatment arm (blue). Blood samples were taken one hour before and
one hour after administration of rhIL1ra (or equivalent timing, but no
drug, in the control group) (red).
Additional file 5. Title of data: Coefficients and p-values of mixed
models. Description of data: There are 12 sheets, with coefficients and p-
values of mixed models corresponding to each of Figures 3-4 A-B and
Additional file 6. In the 6 sheets containing coefficients, maximum and
minimum coefficients for every variable are highlighted at the bottom.
Theoretical equivalent increments required in other variables than infec-
tion to change their respective concentrations of cytokines with max-
imum or minimum coefficients by the same amount as a change from 0
to 1 in “infection” are shown. Furthermore, theoretical equivalent incre-
ments required in other variables than infection to change the concentra-
tions of cytokines with maximum or minimum infection coefficients by
the same amount as a change from 0 to 1 in “infection” are shown. The
remaining 6 sheets contain p-values of coefficients of linear mixed effect
models. Significant values at p < 0.05 were marked with an asterisk in Fig-
ures 3-4 A-B.
Additional file 6. Description of data: Coefficients of linear mixed effect
models, displayed as heatmaps. The colours of the heatmaps are graded
such that red represents positive coefficients and blue represents
negative coefficients. All coefficients are normalized using the quotient of
their standard deviation and that of the dependent variable. Significant
coefficients are highlighted with an asterisk. Independent variables are
along the x-axis and the dependent variable for each model is the
cytokine of the respective row on the y-axis in either (A) the brain
extracellular fluid or (B) arterial blood. Differences in cytokines displayed
between the two subfigures is due to insufficient data to generate all
coefficients from the model.
Additional file 7. Title of data: Principal component analysis of all
cytokines, with additional inflammatory variables. Description of data:
Unlabelled arrows are loadings of cytokines. Labelled and dashed arrows
are post-analysis projections of continuous inflammatory markers. Infec-
tion and non-infection shaded areas show confidence intervals of scores
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